FDA Approved: AUSTEDO XR — Supplemental Application (Teva Neuroscience, Inc.)

View source ↗

Summary

The FDA approved Teva's supplemental application for AUSTEDO XR (deutetrabenazine), an extended-release formulation of Austedo.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease
• Tardive Dyskinesia

Drugs mentioned

• AUSTEDO XR (deutetrabenazine)

Snippet

SUPPL AP for AUSTEDO XR (DEUTETRABENAZINE)